{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T12:19:03Z","timestamp":1775909943432,"version":"3.50.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T00:00:00Z","timestamp":1769644800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T00:00:00Z","timestamp":1769644800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003252","name":"Lund University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003252","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Visual assessment of medial temporal lobe atrophy (MTA) in the clinical workup of cognitive impairment is traditionally corrected for age since MTA increases with age. In addition, common pathologies in the elderly such as amyloid, tau, alpha-synuclein and TDP-43 accumulation as well as white matter hyperintensities representing small vessel disease may affect the association between MTA and age. We investigated this in 949 cognitively unimpaired (CU) and 854 cognitively impaired (CI) individuals focusing on amyloid, tau and alpha-synuclein that at present can be measured in vivo in plasma, CSF or using PET. MTA was associated with age also when these aforementioned pathologies were accounted for. WMH was the strongest and most consistent predictor and mediated 32\u201341% of the association between age and MTA. Secondly, an age-independent cut-off for distinguishing between A\u03b2- CU and A\u03b2\u2009+\u2009CI was derived from 195 CU participants with low levels of pathology. Accuracy, sensitivity and specificity were comparable for our age-independent and previously published age-adjusted cut-offs. In summary, age and WMH emerged as the most prominent factors associated with MTA. Our age-independent cut-off for MTA performed in line with the best performing age-adjusted cut-off, suggesting our more parsimonious proposal could be useful in a clinical setting.<\/jats:p>","DOI":"10.1038\/s41598-025-33602-6","type":"journal-article","created":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T01:35:35Z","timestamp":1769650535000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Medial temporal lobe atrophy is associated with age and pathologies, especially small vessel disease"],"prefix":"10.1038","volume":"16","author":[{"given":"Danielle","family":"van Westen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erik","family":"Stomrud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigi","family":"Lorenzini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian","family":"Palmqvist","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frederik","family":"Barkhof","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oskar","family":"Hansson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Spotorno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,29]]},"reference":[{"key":"33602_CR1","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/BF00308809","volume":"82","author":"H Braak","year":"1991","unstructured":"Braak, H. & Braak, E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 82, 239\u2013259 (1991).","journal-title":"Acta Neuropathol."},{"key":"33602_CR2","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1136\/jnnp.55.10.967","volume":"55","author":"P Scheltens","year":"1992","unstructured":"Scheltens, P. et al. Atrophy of medial temporal lobes on MRI in \u201cprobable\u201d Alzheimer\u2019s disease and normal ageing: Diagnostic value and neuropsychological correlates. J. Neurol. Neurosurg. Psychiatry. 55, 967\u2013972 (1992).","journal-title":"J. Neurol. Neurosurg. Psychiatry."},{"key":"33602_CR3","doi-asserted-by":"publisher","first-page":"2771","DOI":"10.1093\/brain\/awab114","volume":"144","author":"D Berron","year":"2021","unstructured":"Berron, D. et al. Early stages of tau pathology and its associations with functional connectivity, atrophy and memory. Brain 144, 2771\u20132783 (2021).","journal-title":"Brain"},{"key":"33602_CR4","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1002\/hipo.22690","volume":"27","author":"CM Fiford","year":"2017","unstructured":"Fiford, C. M. et al. White matter hyperintensities are associated with disproportionate progressive hippocampal atrophy. Hippocampus 27, 249\u2013262 (2017).","journal-title":"Hippocampus"},{"key":"33602_CR5","doi-asserted-by":"publisher","first-page":"3147","DOI":"10.1007\/s00330-016-4726-3","volume":"27","author":"JJ Claus","year":"2017","unstructured":"Claus, J. J. et al. Practical use of visual medial temporal lobe atrophy cut-off scores in Alzheimer\u2019s disease: Validation in a large memory clinic population. Eur Radiol. 27, 3147\u20133155 (2017).","journal-title":"Eur Radiol."},{"key":"33602_CR6","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1161\/01.STR.0000236555.87674.e1","volume":"37","author":"FE De Leeuw","year":"2006","unstructured":"De Leeuw, F. E., Korf, E., Barkhof, F. & Scheltens, P. White matter lesions are associated with progression of medial temporal lobe atrophy in Alzheimer disease. Stroke 37, 2248\u20132252 (2006).","journal-title":"Stroke"},{"key":"33602_CR7","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1016\/j.neurobiolaging.2013.02.002","volume":"34","author":"L Clerx","year":"2013","unstructured":"Clerx, L. et al. Measurements of medial temporal lobe atrophy for prediction of Alzheimer\u2019s disease in subjects with mild cognitive impairment. Neurobiol. Aging. 34, 2003\u20132013 (2013).","journal-title":"Neurobiol. Aging."},{"key":"33602_CR8","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.neurobiolaging.2019.07.005","volume":"82","author":"RL Nosheny","year":"2019","unstructured":"Nosheny, R. L. et al. Associations among amyloid status, age, and longitudinal regional brain atrophy in cognitively unimpaired older adults. Neurobiol. Aging. 82, 110\u2013119 (2019).","journal-title":"Neurobiol. Aging."},{"key":"33602_CR9","doi-asserted-by":"publisher","first-page":"3192","DOI":"10.1523\/JNEUROSCI.3769-16.2017","volume":"37","author":"SM Marks","year":"2017","unstructured":"Marks, S. M., Lockhart, S. N., Baker, S. L. & Jagust, W. J. Tau and \u03b2-Amyloid are associated with medial temporal lobe structure, function, and memory encoding in normal aging. J. Neurosci. 37, 3192\u20133201 (2017).","journal-title":"J. Neurosci."},{"key":"33602_CR10","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1186\/s12883-021-02325-2","volume":"21","author":"A Molinder","year":"2021","unstructured":"Molinder, A., Ziegelitz, D., Maier, S. E. & Eckerstr\u00f6m, C. Validity and reliability of the medial temporal lobe atrophy scale in a memory clinic population. BMC Neurol. 21, 289 (2021).","journal-title":"BMC Neurol."},{"key":"33602_CR11","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1111\/joim.12358","volume":"278","author":"D Ferreira","year":"2015","unstructured":"Ferreira, D. et al. Practical cut-offs for visual rating scales of medial temporal, frontal and posterior atrophy in Alzheimer\u2019s disease and mild cognitive impairment. J. Intern. Med. 278, 277\u2013290 (2015).","journal-title":"J. Intern. Med."},{"key":"33602_CR12","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1038\/s41467-017-01150-x","volume":"31","author":"S Palmqvist","year":"2017","unstructured":"Palmqvist, S. et al. Earliest accumulation of \u03b2-amyloid occurs within the default-mode network and concurrently affects brain connectivity. Nat. Commun. 31, 1214 (2017).","journal-title":"Nat. Commun."},{"key":"33602_CR13","doi-asserted-by":"publisher","first-page":"5481","DOI":"10.1038\/s41380-021-01249-0","volume":"26","author":"H Hampel","year":"2021","unstructured":"Hampel, H. et al. The amyloid-beta pathway in Alzheimer\u2019s disease. Mol. Psychiatry. 26, 5481\u20135503 (2021).","journal-title":"Mol. Psychiatry."},{"key":"33602_CR14","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/0197-4580(95)00021-6","volume":"16","author":"H Braak","year":"1995","unstructured":"Braak, H. & Braak, E. Staging of Alzheimer\u2019s disease-related neurofibrillary changes. Neurobiol. Aging. 16, 271\u2013278 (1995).","journal-title":"Neurobiol. Aging."},{"key":"33602_CR15","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1097\/NEN.0b013e31825018f7","volume":"71","author":"PT Nelson","year":"2012","unstructured":"Nelson, P. T. et al. Correlation of Alzheimer disease neuropathologic changes with cognitive status: A review of the literature. J. Neuropathol. Exper. Neurol. 71, 362\u2013381 (2012).","journal-title":"J. Neuropathol. Exper. Neurol."},{"key":"33602_CR16","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.neurobiolaging.2021.09.017","volume":"109","author":"LE Wisse","year":"2022","unstructured":"Wisse, L. E. et al. Tau pathology mediates age effects on medial temporal lobe structure. Neurobiol. Aging. 109, 135\u2013144 (2022).","journal-title":"Neurobiol. Aging."},{"key":"33602_CR17","doi-asserted-by":"publisher","first-page":"e44","DOI":"10.1161\/STR.0000000000000116","volume":"48","author":"EE Smith","year":"2017","unstructured":"Smith, E. E. et al. Prevention of stroke in patients with silent cerebrovascular disease: A scientific statement for healthcare professionals from the American heart association\/American stroke association. Stroke 48, e44\u2013e71 (2017).","journal-title":"Stroke"},{"key":"33602_CR18","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.030676","volume":"12","author":"F Koohi","year":"2023","unstructured":"Koohi, F., Harshfield, E. L. & Markus, H. S. Contribution of conventional cardiovascular risk factors to brain white matter hyperintensities. J. Am. Heart Assoc. 12, e030676 (2023).","journal-title":"J. Am. Heart Assoc."},{"key":"33602_CR19","doi-asserted-by":"publisher","first-page":"3047","DOI":"10.1161\/STROKEAHA.125.051159","volume":"56","author":"JM Biesbroek","year":"2025","unstructured":"Biesbroek, J. M. et al. Signature white matter hyperintensity locations associated with vascular risk factors derived from 15 653 individuals. Stroke 56, 3047\u20133059 (2025).","journal-title":"Stroke"},{"key":"33602_CR20","doi-asserted-by":"publisher","first-page":"88","DOI":"10.3389\/fnana.2016.00088","volume":"10","author":"Y Wu","year":"2016","unstructured":"Wu, Y., Sun, D., Wang, Y. & Wang, Y. Subcomponents and connectivity in the inferior frontal-occipital fasciculus revealed by diffusion spectrum imaging fiber tracking. Front. Neuroanat. 10, 88 (2016).","journal-title":"Front. Neuroanat."},{"key":"33602_CR21","doi-asserted-by":"publisher","first-page":"4262","DOI":"10.1002\/alz.13372","volume":"19","author":"A Garnier-Crussard","year":"2023","unstructured":"Garnier-Crussard, A. & Ch\u00e9telat, G. White matter hyperintensities in Alzheimer\u2019s disease: Beyond (but not instead of) the vascular contribution. Alzheimers Dement. 19, 4262\u20134263 (2023).","journal-title":"Alzheimers Dement."},{"key":"33602_CR22","doi-asserted-by":"publisher","first-page":"fcaa132","DOI":"10.1093\/braincomms\/fcaa132","volume":"2","author":"KK Laing","year":"2020","unstructured":"Laing, K. K. et al. Cerebrovascular disease promotes tau pathology in Alzheimer\u2019s disease. Brain Commun. 2, fcaa132 (2020).","journal-title":"Brain Commun."},{"key":"33602_CR23","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s00401-021-02397-x","volume":"143","author":"A Kapasi","year":"2022","unstructured":"Kapasi, A. et al. Association of small vessel disease with tau pathology. Acta Neuropathol. 143, 349\u2013362 (2022).","journal-title":"Acta Neuropathol."},{"key":"33602_CR24","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1002\/ana.26711","volume":"94","author":"PT Nelson","year":"2023","unstructured":"Nelson, P. T., Schneider, J. A., Jicha, G. A., Duong, M. T. & Wolk, D. A. When Alzheimer\u2019s is LATE: Why does it matter?. Ann. Neurol. 94, 211\u2013222 (2023).","journal-title":"Ann. Neurol."},{"key":"33602_CR25","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1093\/brain\/awz099","volume":"142","author":"PT Nelson","year":"2019","unstructured":"Nelson, P. T. et al. Limbic-predominant age-related TDP-43 encephalopathy (LATE): Consensus working group report. Brain 142, 1503\u20131527 (2019).","journal-title":"Brain"},{"key":"33602_CR26","doi-asserted-by":"publisher","first-page":"117","DOI":"10.3389\/fnagi.2017.00117","volume":"9","author":"HFM Rhodius-Meester","year":"2017","unstructured":"Rhodius-Meester, H. F. M. et al. MRI visual ratings of brain atrophy and white matter hyperintensities across the spectrum of cognitive decline are differently affected by age and diagnosis. Front. Aging Neurosci. 9, 117 (2017).","journal-title":"Front. Aging Neurosci."},{"key":"33602_CR27","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1212\/01.wnl.0000277459.83543.99","volume":"69","author":"F Barkhof","year":"2007","unstructured":"Barkhof, F. et al. The significance of medial temporal lobe atrophy: A postmortem MRI study in the very old. Neurology 69, 1521\u20131527 (2007).","journal-title":"Neurology"},{"key":"33602_CR28","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1001\/jama.2020.12134","volume":"324","author":"S Palmqvist","year":"2020","unstructured":"Palmqvist, S. et al. Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders. JAMA 324, 772\u2013781 (2020).","journal-title":"JAMA"},{"key":"33602_CR29","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1001\/jamaneurol.2019.1632","volume":"76","author":"S Palmqvist","year":"2019","unstructured":"Palmqvist, S. et al. Performance of fully automated plasma assays as screening tests for Alzheimer disease-related beta-amyloid status. JAMA Neurol. 76, 1060\u20131069 (2019).","journal-title":"JAMA Neurol."},{"key":"33602_CR30","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1038\/s41591-021-01348-z","volume":"27","author":"S Palmqvist","year":"2021","unstructured":"Palmqvist, S. et al. Prediction of future Alzheimer\u2019s disease dementia using plasma phospho-tau combined with other accessible measures. Nat. Med. 27, 1034\u20131042 (2021).","journal-title":"Nat. Med."},{"key":"33602_CR31","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) 607\u2013608 (American Psychiatric Publishing, 2013).","DOI":"10.1176\/appi.books.9780890425596"},{"key":"33602_CR32","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/S1474-4422(21)00066-1","volume":"20","author":"B Dubois","year":"2021","unstructured":"Dubois, B. et al. Clinical diagnosis of Alzheimer\u2019s disease: Recommendations of the International Working Group. Lancet Neurol. 20, 484\u2013496 (2021).","journal-title":"Lancet Neurol."},{"key":"33602_CR33","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1038\/s43587-023-00471-5","volume":"3","author":"WS Brum","year":"2023","unstructured":"Brum, W. S. et al. A two-step workflow based on plasma p-tau217 to screen for amyloid \u03b2 positivity with further confirmatory testing only in uncertain cases. Nat. Aging. 3, 1079\u20131090 (2023).","journal-title":"Nat. Aging."},{"key":"33602_CR34","doi-asserted-by":"publisher","first-page":"6635","DOI":"10.1038\/s41467-022-34129-4","volume":"13","author":"A Pichet Binette","year":"2022","unstructured":"Pichet Binette, A. et al. Amyloid-associated increases in soluble tau relate to tau aggregation rates and cognitive decline in early Alzheimer\u2019s disease. Nat. Commun. 13, 6635 (2022).","journal-title":"Nat. Commun."},{"key":"33602_CR35","doi-asserted-by":"publisher","first-page":"3555","DOI":"10.1038\/s41467-021-23746-0","volume":"12","author":"NC Cullen","year":"2021","unstructured":"Cullen, N. C. et al. Plasma biomarkers of Alzheimer\u2019s disease improve prediction of cognitive decline in cognitively unimpaired elderly populations. Nat. Commun. 12, 3555 (2021).","journal-title":"Nat. Commun."},{"key":"33602_CR36","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1002\/alz.12751","volume":"19","author":"S Palmqvist","year":"2023","unstructured":"Palmqvist, S. et al. An accurate fully automated panel of plasma biomarkers for Alzheimer\u2019s disease. Alzheimers Dement. 19, 1204\u20131215 (2023).","journal-title":"Alzheimers Dement."},{"key":"33602_CR37","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1001\/jamaneurol.2020.0989","volume":"77","author":"A Leuzy","year":"2020","unstructured":"Leuzy, A. et al. Diagnostic performance of RO948 F 18 tau positron emission tomography in the differentiation of Alzheimer disease from other neurodegenerative disorders. JAMA Neurol. 77, 955\u2013965 (2020).","journal-title":"JAMA Neurol."},{"key":"33602_CR38","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.neuroimage.2016.09.011","volume":"143","author":"O Puonti","year":"2016","unstructured":"Puonti, O., Iglesias, J. E. & Van Leemput, K. Fast and sequence-adaptive whole-brain segmentation using parametric Bayesian modeling. Neuroimage 143, 235\u2013249 (2016).","journal-title":"Neuroimage"},{"key":"33602_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroimage.2020.117471","volume":"225","author":"S Cerri","year":"2021","unstructured":"Cerri, S. et al. A contrast-adaptive method for simultaneous whole-brain and lesion segmentation in multiple sclerosis. Neuroimage 225, 117471 (2021).","journal-title":"Neuroimage"},{"key":"33602_CR40","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.jalz.2015.09.009","volume":"12","author":"T Bittner","year":"2016","unstructured":"Bittner, T. et al. Technical performance of a novel, fully automated electrochemiluminescence immunoassay for the quantitation of \u03b2-amyloid (1\u201342) in human cerebrospinal fluid. Alzheimers Dement. 12, 517\u20131526 (2016).","journal-title":"Alzheimers Dement."},{"key":"33602_CR41","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1212\/WNL.0000000000200878","volume":"99","author":"G Bellomo","year":"2022","unstructured":"Bellomo, G. et al. alpha-Synuclein seed amplification assays for diagnosing synucleinopathies: The way forward. Neurology 99, 195\u2013205 (2022).","journal-title":"Neurology"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-33602-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-33602-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-33602-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T22:02:55Z","timestamp":1769724175000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-33602-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,29]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["33602"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-33602-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,29]]},"assertion":[{"value":"19 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3912"}}